Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
COHO building presure .0011x.0012
AFFYis running nicely with the catalyst this month some will sell just before and some will hang on. If its PDUFA is passed this
one goes to near 20. jmho
CSKH @.003x.0033
link back
just like miky d's aye
CSKH .0032's up L2 gaining action and strength
re CSKH 2mm up @.003
very nice!
man look at the bid suport that just came in on CSKH link back for chart
I think so too
re CSKH look'n for .005+ tomorrow
CSKH @.003x.0031
link back
SNDY act's like the float is locked up over .01's could be a wiled ride link back for chart
P.S. I NEED ALL I CAN GET
re CSKH yes expecting another big day tomorrow
CSKH could be a good morning mover up 34%
strong stock looking for .02 .05 over the next few weeks waiting on CE mark approval
COHO .0012's getting hit
both FUEL & PRMW very nice lookers
ty for the charts
please drop a chart here any time
thx again
CSKH @.0026x.0027
link back
CSKH @.0025x.0026
link back
looking like the bears are having a day of it
gmorning & yes CSKH is look'n very good this morning
goodmorning CSKH looking good AGEY ameritrade wont let me open on it
TRGTwill tumble today on this bad news
Targacept and AstraZeneca (AZN) announce remaining TC-5214 Phase 3 efficacy studies do not meet primary endpoint; regulatory filing will not be pursued (TRGT) 7.41 : AstraZeneca (AZN) and Targacept announce top-line results from the remaining Phase 3 studies investigating efficacy, tolerability and safety of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder who did not respond adequately to initial antidepressant treatment. RENAISSANCE 4 and RENAISSANCE 5, both efficacy and tolerability studies, did not meet the primary endpoint of change on the Montgomery-Asberg Depression Rating Scale total score after eight weeks of adjunct treatment with TC-5214 as compared to placebo. These studies conclude the RENAISSANCE Program for TC-5214. Based on the totality of the results, AstraZeneca and Targacept will not pursue a regulatory filing for TC-5214 as an adjunct treatment for patients with MDD.
It still has TC 5619,6987,6683 but all are in phase 2 not phase 3. June 30th will temper todays drop in that TC6987 topline data is due 6/30 and it is not part of the above.
Many times you get a 40-50% drop with news such as the above but I am thinking a 20- 25% drop should be as dramatic as it gets today and then it levels then climbs a bit before the end of June.
Jmho
ADHC Shares Outstanding5: 980.78M
SNDY penny land link back for chart
GM MTC hope all is well. Perhaps we can work on teaching Govn't how to SPELL - "Fiscal Responsibility", or in the case of the administration, just "self responsibility" would be great.
Politicians on both sides suck at taking credit for their own missteps,lies, and general incompetence, until they get caught red handed with stains on a dress, or bogged down in a senseless war, or fraud as in the case of the "post office scandal" (by congress in the late 80s), or the chronic lack of an energy policy which has been the case for over 40 years etc.
Give me Lincoln, Washington, Jefferson, I am really sick of this crap we have. lol
Strength: | Medium-Full Bodied |
Origin: | Nicaragua |
Wrpeapr: | Habano |
Shape: | Straight |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |